… target spike, we may deduce optimal combinations of monoclonal antibodies (mAbs) to
prevent and treat infection by emerging variants and to minimize the risk of viral escape. We can …

… development of neutralizing antibodies against COVID-… antibody development pipeline to
combat the potential escape plans of SARS-CoV-2, including somatic mutations and antibody-…

… binding SARS- CoV- 2 spike by combining in vivo antibody … spike nanobodies and their
combinations by complementary … This work thus provides significant impacts on SARS- CoV- 2 …

… Combining RDV and antibodies … to treat SARS-CoV-2 infections and the continued clinical
development of the C144 and C135 antibody combination to treat patients infected with SARS-…

… ; Figure 2) in combination with etesevimab (also known as LY-CoV016 or LY3832479). In
a phase II clinical trial, this combination significantly decreased SARS-CoV-2 log viral load in …

… and quality of the antibody responses towards both a homologous SARS-CoV-2 virus and a
… antibodies conferred robust protection against challenge with the heterologous SARS-CoV-…

… However, by reducing the selecting concentration of C549 and sequential passaging with
antibody 4 times, we obtained rVSV/SARSCoV-2 populations in which Y449H, E484K, F486L, …

… combination of different NAbs are evaluated. Besides the VH3-53/VH3-66 antibodies, further
… able to bind RBD together with two other antibodies: S309 and CR3022 (Figure S7). These …

… elicited antibodies neutralized the B.1.526 variant. One of the Regeneron therapeutic …
antibodies was less effective against the B.1.526 (E484K) variant but the two-antibody combination …

… Potent neutralising antibodies to the RBD of SARS-CoV-2 … -RBD interaction by anti-RBD
antibodies in two assays (Fig 3, … monoclonal antibody combination against SARS coronavirus…